An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "mAbs"
DOI: 10.1080/19420862.2022.2088454
Abstract: ABSTRACT Monoclonal antibodies targeting the programmed cell death protein 1 (PD-1) remain the most prevalent cancer immunotherapy both as a monotherapy and in combination with additional therapies. Despite the extensive success of anti-PD-1 monoclonal antibodies… read more here.
Keywords: anti immunotherapy; immunotherapy; affinity; maximum efficacy ... See more keywords